The combined effect is sustainable and safe weight loss for people who take a GLP-1 agonist medication under medical supervision, according to a clinical review of GLP-1 receptor agonists published in Drugs in Context
At the start of treatment with Wegovy, many people begin noticing small changes within the first few weeks, such as reduced appetite, fewer cravings, or feeling full sooner
It increases glucose uptake at a cellular level, bringing blood sugar levels down rather than up (as with GH)
Tirzepatide, another GLP-1 receptor agonist, works by targeting multiple metabolic pathways to promote weight loss
In some cases, schwannomas may cause symptoms or affect nerve function, leading to pain, weakness, or sensory disturbances